Brain metastases are one of the most severe complications of melanoma, the most aggressive type of skin cancer. Researchers ...

The recent volatility in our stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy, but I want to reassure our investors that there have ...

Turner Construction has announced the topping out of McGivney Tower, which marked the conclusion of vertical construction for the Adams Neurosciences Center at Yale New Haven Hospital, Saint Raphael ...

Jupiter Neurosciences (JUNS) issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company currently valued at $34.1 million, has announced a partnership with Catalent (NYSE:CTLT) Pharma ...

Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, ...

Jupiter Neurosciences, Inc.’s JUNS share price has dipped by 59.50%, which has investors questioning if this is right time to ...

Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Jupiter Neurosciences董事长兼首席执行官Christer Rosén强调与Catalent合作的重要性，称赞其"领先业界的制药生产专业知识"以及高效扩大生产规模的能力。这一步骤被认为对推进JOTROL™进入帕金森病的临床开发阶段至关重要。

佛罗里达州朱庇特 - 市值为4039万美元的临床阶段制药公司Jupiter Neurosciences, Inc. (NASDAQ: JUNS)宣布与Zina Biopharmaceuticals, LLC建立战略合作伙伴关系，以推进其帕金森病二期a临床试验。根据 InvestingPro ...